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Abstract
Various kinetic parameters of serum CA-125 have been reported to have better correlation
with outcomes for patients treated with neoadjuvant chemotherapy (NAC). This study aimed
to compare the available kinetic parameters of serum CA-125 in an external cohort of
advanced-stage ovarian cancer. Using the cancer registry databases from the Yonsei Can-
cer Hospital, we retrospectively reviewed 210 patients with advanced-stage ovarian cancer,
treated with NAC followed by interval debulking surgery. We compared area under the
receiver-operating characteristics curves (AUCs), false negative rate, and negative predic-
tive value (NPV) using 10 different models for optimal cytoreduction and platinum resis-
tance. In addition, we compared incremental AUC for progression-free survival (PFS) and
overall survival (OS). No gross residual tumor was observed in 37.0% and residual tumors
<1 cm in 82.2% of patients. No model using CA-125 kinetic parameters had an AUC higher
than >0.6 for predicting optimal cytoreduction. After adjusting for age, BMI, disease stage,
and histologic subtypes, all models had an AUC >0.70 for predicting platinum resistance.
However, no model had a high enough NPV (highest value = 82.0%) to avoid chemotherapy
futility. For survival outcomes, no model had an incremental AUC >0.70 for predicting either
PFS or OS. None of the proposed serum CA-125 kinetic parameters showed high accuracy
in predicting optimal cytoreduction, platinum resistance, or survival in patients receiving
NAC. For advanced-stage ovarian cancer treated with NAC, there is a need to discover reli-
able biomarkers to better stratify patient response groups for optimal treatment decision-
making.
Introduction
Epithelial ovarian cancer is the leading cause of death among all gynecological malignancies in
Korea [1, 2]. The standard therapy of advanced-stage ovarian cancer includes primary
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debulking surgery (PDS), followed by platinum-based combination chemotherapy. Recently,
several phase 3 clinical trials showed that neoadjuvant chemotherapy (NAC) followed by inter-
val debulking surgery (IDS), was not an inferior treatment course compared to PDS for treat-
ing advanced-stage ovarian cancer [3–6]. NAC followed by IDS has gained popularity as an
alternative approach that may reduce perioperative morbidity.
A potential advantage of the NAC approach is that it can provide the treating clinician with
early information regarding chemotherapy response using clinical, radiological, and tumor
markers. As chemo-sensitivity during NAC has been a well-known prognostic factor for sur-
vival in advanced-stage ovarian cancer [7, 8], identifying a patient as either a good responder
or poor responder to NAC before IDS is important to triage further adjuvant treatment.
Cancer antigen-125 (CA-125) is the only serological biomarker in routine use for evaluating
disease status and monitoring the efficacy of chemotherapy for the management of patients
with epithelial ovarian cancer. In the neoadjuvant setting, where the effect of surgery is
excluded, the value of CA-125 is expected to be correlated with NAC response. Therefore, 10
different models for the evaluation of CA-125 regression during NAC, as a predictor of opti-
mal cytoreduction during IDS or a prognostic factor for survival, have been proposed in the lit-
erature [9–18]. Various kinetic parameters of CA-125 have been evaluated for optimal
cytoreduction, platinum resistance, and patient survival.
Identifying a patient as either a good or poor responder to treatment can be useful at two
levels. First, such a prediction for optimal cytoreduction at IDS may offer better patient
counseling by preventing futile surgery. Second, postoperative adjuvant chemotherapy
(POAC) could be tailored according to the prediction of platinum resistance. For poor
responders, clinical trials with other biologic agents could be applied with molecular profiling
instead of conventional chemotherapy.
The aim of this study was to compare 10 previous studies using various kinetic parameters
of serum CA-125 as a predictive or prognostic factor, as well as to validate the results in an
external cohort of advanced-stage ovarian cancer treated with NAC.
Materials and methods
Study population
The electronic medical records of patients diagnosed between 2008 and 2016 with epithelial
ovarian, fallopian tube, and primary peritoneal carcinoma, who received NAC followed by
IDS at the Department of Obstetrics and Gynecology, Severance Hospital, Yonsei University
College of Medicine, were retrospectively analyzed. The disease stage of these patients was
based on biopsy or cytology and the extent of disease according to radiological imaging. The
present study was reviewed and approved by the institutional review board at Severance Hos-
pital, Yonsei University Health System, Seoul, Korea.
In brief, the inclusion criteria were as follows: (1) histopathologically confirmed FIGO stage
III or IV ovarian, fallopian tube, and primary peritoneal carcinoma; (2) patients who under-
went IDS following NAC; (3) patients having received more than 1 cycle of NAC before IDS.
The exclusion criteria were as follows: patients with FIGO stage I or II (N = 5), patients who
have not received IDS after NAC (N = 2), those who were lost to follow-up (N = 2), and
patients who have not received platinum-based chemotherapy (N = 4). Ultimately, the final
study population comprised 197 female patients (S1 Fig).
The characteristics of the study patients are shown in Table 1. We retrospectively collected
data from medical records, including age, body mass index (BMI), disease characteristics (his-
tology, FIGO stage), residual disease after IDS, date of progression or recurrence, date of last
follow-up, and patient disease status at last contact. All patients underwent surgery with intent
CA-125 in advanced-stage ovarian cancer
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to achieve complete cytoreduction (no gross residual disease). Surgery was considered “radi-
cal” if the procedures included upper abdomen surgery, bowel resection, or video-assisted
thoracoscopic surgery (VATS). Diagnosis of recurrence was based on radiological imaging,
and/or histology diagnosis ultimately determined by gynecology oncologists. The treatment-
free interval (TFI) was defined as the interval from the end of platinum-based chemotherapy
to the first recurrence. A threshold value for TFI of 6 months was applied to qualify a patient
as having platinum-sensitive disease.
Ethical considerations
This retrospective study was approved by the Institutional Review Board of Severance Hospital
at Yonsei University College of Medicine (IRB No. 4-2018-0518). The patient records were
anonymized and de-identified prior to analysis.
Measurement of CA-125
For each patient, CA-125 levels from pre-NAC to post-POAC were recorded. CA-125 levels
were measured initially (before the first cycle of NAC), then every 3 weeks before
Table 1. Patient characteristics (N = 197).
Characteristics
Median age, years (range) 57 (27–80)
Median CA-125 level, U/mL (range) 1825.7 (44.3–30000.0)
Median CA-125 level before IDS, U/mL (range) 45.6 (4.0–7913.1)
FIGO stage, n (%)
IIIB 7 (3.6%)
IIIC 45 (22.8%)
IVA 89 (45.2%)
IVB 56 (28.4%)
Histologic type, n (%)
HGSC 180 (91.4%)
Non-HGSC 17 (8.6%)
Radical surgerya, n(%)
None
Any radical surgery
Residual disease after IDS, n (%)
No gross 72 (36.6%)
0.5cm 63 (32.0%)
0.5-1cm 27 (13.7%)
1-2cm 5 (2.5%)
>2cm 8 (4.1%)
NA 22 (11.2%)
Cycles of total chemotherapy, n (%)
<6 8 (4.1%)
6 189 (95.9%)
aRadical surgery includes any of following: bowel surgery, video-assisted thoracoscopic surgery, splenectomy, liver
resection, supraclavicular fossa resection, ureter resection, and others.
BMI, body mass index; CA-125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics;
HGSC, high-grade serous carcinoma.
https://doi.org/10.1371/journal.pone.0203366.t001
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chemotherapy. The B-R-A-H-M-S CA-125 II KryptorR technique, an automatic immunofluo-
rescence analysis kit used to measure CA-125 in the serum or plasma, was used to assay CA-
125. A concentration of CA-12535 UI/mL was considered normal.
Statistical analysis
Discrimination was quantified using the area under the curve (AUC) from receiver operating
characteristic (ROC) analysis. The AUC corresponds to the overall predictive validity. The
AUC reflects the ability of a test to discriminate between a diseased and a non-diseased subject
across all possible levels of positivity. False negative (FN) rates and negative predictive values
(NPVs) were also evaluated. We compared C-statistics for survival. The expected value of the
C-index is 0.5 for a model with no explanatory power. C-index achieves its maximum value of
1.0 when the model assigns a lower probability of occurrence to all cases with no adverse
events than to any cases with an adverse event. Progression-free survival (PFS) was defined as
the interval between the date of diagnosis and the date of first recurrence. Overall survival
(OS) was defined as the interval between the date of diagnosis and the date of death. Statistical
analyses were conducted with SAS software (version 9.2; SAS Institute, Cary, NC). For all anal-
yses, P< 0.05 was considered statistically significant.
Results
Description of various kinetic parameters of CA-125
Ten models developed to predict optimal cytoreduction, platinum resistance, and survival
were identified from the medical literature using PubMed. Seven models were designed to pre-
dict optimal cytoreduction and 2 models were derived to predict platinum-resistance. All
models evaluated PFS and OS. Nine models classified patients as being either good or poor
responders for NAC (binary models). The most important characteristics of each model are
summarized in Table 2.
Various kinetic parameters of CA-125 were obtained from published formulas. Before
applying the model to the patient data to calculate individual kinetic parameters of CA-125,
we investigated whether a patient’s characteristics made them eligible for the specific model.
Patients were only evaluated in each prediction model based on the inclusion criteria for the
specific prediction model. Most models were designed to calculate CA-125 for FIGO stage III
or IV [9–13, 16, 18]. Model 6 was designed to calculate CA-125 in patients with FIGO stage III
[14], and model 9 was designed to calculate CA-125 in patients with FIGO stage II–IV disease
[17]. In contrast, most models were designed to calculate CA-125, regardless of the histology
of the disease [9–17]. Model 10 was designed to calculate CA-125, excluding clear cell carci-
noma and mucinous adenocarcinoma [18]. All models reported cut-off values that allowed for
the identification of patients who were good responder to chemotherapy. The cut-off values
for each model are shown in Table 2. In model 1, 3, 6, and 7, the CA-125 value before IDS was
used [9, 11, 14, 15], and model 2, 5, 9 used the CA-125 value after 3 cycles of NAC [10, 13, 17].
Model 8 and 10 used regression coefficients, which were calculated using CA-125 levels from
the time of NAC initiation until CA-125 normalization, or the day of IDS [16, 18]. Model 4
used the percent reduction in CA-125 (from pre-NAC to pre-IDS value) [12].
Prediction for optimal cytoreduction
Among the 197 study patients, 72 (36.6%) had no gross residual disease after IDS. In addition,
162 patients (82.2%) achieved optimal cytoreduction with residual tumors <1 cm after IDS.
CA-125 in advanced-stage ovarian cancer
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All CA-125 models were applied for the prediction of no gross residual tumor and optimal
cytoreduction. The number of patients, AUC, FN rate, NPV, and patients classified as good
responders are shown in Table 3. None of models using CA-125 kinetic parameters predicted
surgical outcome accurately, and no model had an AUC higher than 0.60.
Prediction for platinum-resistance
The ROC curves are plotted in Fig 1. When adjusted for age, BMI, disease stage, and histologic
subtype, the model with the highest AUC was that reported by Le et al. using CA-125 normali-
zation after NAC, with an AUC of 0.80 (95% confidence interval (CI): 0.734–0.864). The other
model gave a performance with AUC values ranging from 0.70–0.79 (S1 Table). However,
none of the models had acceptable FN rate (<5%) or enough NPV (>90%).
Prediction for survival
When adjusting for age, BMI, disease stage, and histologic subtype, all models had a significant
prognostic factor for PFS and OS. All models gave performances ranging from 0.65–0.70 for
iAUC and the Harrell’s C-index ranged from 0.70–0.76 for PFS and OS (S2 Table). However,
none of the 10 models investigated had an iAUC >0.7 or a C-index >0.8 for the prediction of
either PFS or OS.
Table 2. Description of regression models to predict CA-125 values during neoadjuvant chemotherapy.
No. Models Stage NAC cycles,
median
N Chemotherapy
regimen
CA125 before NAC (UI/
mL)
CA125 cut-off (UI/mL) Outcomes
1 Zeng et al.(2016) IIIC-IV 1–3 (97.5%)
(range, 1–7)
118 Paclitaxel + Platinum 1814
(56.6–56541.0)
Before IDS200 Complete cytoreduction
Chemotherapeutic
sensitivity
PFS, OS
2 Pelissier et al.
(2016)
IIIC-IV 5.6 (range, 4–6) 142 Platinum-based 2128.7
(15–16275)
After the 3rd cycle of
NAC <35
Platinum sensitivity
PFS, OS
3 Morimoto et al.
(2016)
III-IV 4 (range, 3–6) 139 Paclitaxel
+carboplatin
1578
(33.1–26606)
Before IDS25.8 Complete cytoreduction
PFS, OS
4 Mahdi et al.
(2015)
IIIC-IV 4 (range, 3–6) 115 Platinum-based 905.5
(47–20,000)
Reduction90%
(Before NAC/ Before
IDS)
Complete cytoreduction
PFS, OS
5 Pelissier et al.
(2014)
IIIC-IV 5.6 (range, 1–9) 148 Taxane + platinum 2122
(15–26,220)
After the 3rd cycle of
NAC <75
Complete cytoreduction
PFS, OS
6 Furukawa et al.
(2013)
III 3 75 Taxane + platinum Complete IDS:
639 (57–6,593)
Non-complete IDS: 1427
(45–10,989)
Before IDS 20 Complete cytoreduction
PFS, OS
7 Rodriguez et al.
(2012)
IIIC-IV 3 (range, 1–8) 103 Taxane + platinum 1749
(38–10,150)
Before IDS100 Complete cytoreduction
PFS, OS
8 Vasudev et al.
(2011)
III-IV Not reported
(range, 3–6)
63 Platinum-based 1250
(53–16,398)
Half-life <12 days, >18
days
Regression coefficient
-0.039
Optimal cytoreduction
PFS, OS
9 Le et al.(2008) II-IV Not reported 90 Taxane + platinum Not reported Before IDS <35 PFS, OS
10 Tate et al.(2005) IIIC-IV 4.5 50 Platinum-based Good responder: 2843
Poor responder: 3697
Regression coefficient
>-0.039
3-year survival
PFS, OS
NAC, neoadjuvant chemotherapy; IDS, interval debulking surgery; PFS, progression-free survival; OS, overall survival.
https://doi.org/10.1371/journal.pone.0203366.t002
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Discussion
Our study evaluated and compared the performance of 10 models currently available to pre-
dict optimal cytoreduction, platinum-resistance, and survival outcomes in patients undergoing
IDS after NAC for advanced-stage ovarian cancer. The 10 models were all applied to an inde-
pendent cohort of advanced-stage ovarian cancer. This study shows the limited usefulness of
using CA-125 kinetic parameters for predicting patient outcomes. In particular, none of the 10
models had high accuracy in predicting optimal cytoreduction, platinum-resistance, or sur-
vival outcomes.
Ovarian cancer is one of the most chemo-sensitive of all solid tumors, with over 80% of
patients showing a response to standard platinum-based chemotherapy. Even if preoperative
imaging shows massive ascites and diffuse dissemination, some patients still achieved a nearly
complete response with IDS after NAC treatment. In addition, these subgroups had better sur-
vival than the poor responder group after NAC. Therefore, identifying good and poor
responders after NAC, but before IDS, is an important issue for the following reasons. First,
prediction for optimal cytoreduction at IDS may offer patient counseling by preventing futile
surgery. Second, POAC could be tailored according to the prediction of platinum resistance.
Third, response to NAC could be used as a surrogate for survival. However, there is no reliable
biomarker at present other than CA-125 for identifying good responders/poor responders
after NAC.
CA-125 is still the only tumor marker that is recommended as a diagnostic or prognostic
indicator, as well as for monitoring the efficacy of chemotherapy and disease recurrence after
surgery. CA-125 is routinely used to assess response to chemotherapy and, together with
Table 3. Evaluation of models to predict residual disease.
Predicting R0 after IDS
No. Model No. of patients No residual tumor AUC 95% CI FN rate NPV Patients assigned to the good responder
1 Zeng et al.(2016) 193 68/193 (35.2%) 0.50 0.44–0.56 80.0% 35.1% 39/193 (20.2%)
2 Pelissier et al.(2016) 184 65/184 (35.3%) 0.55 0.48–0.63 34.5% 41.4% 114/193 (59.1%)
3 Morimoto et al.(2016) 193 68/193 (35.2%) 0.57 0.50–0.64 32.0% 43.7% 122/193 (63.2%)
4 Mahdi et al.(2015) 201 72/201 (35.8%) 0.52 0.46–0.58 72.9% 36.9% 52/201 (25.9%)
5 Pelissier et al.(2014) 184 65/184 (35.3%) 0.53 0.46–0.60 58.8% 37.5% 72/184 (39.1%)
6 Furukawa et al.(2013) 193 68/193 (35.2%) 0.56 0.49–0.63 27.2% 43.3% 133/193 (68.9%)
7 Rodriguez et al.(2012) 193 68/193 (35.2%) 0.50 0.43–0.57 68.8% 35.3% 60/193 (31.1%)
8 Vasudev et al.(2011) 194 69/194 (35.6%) 0.51 0.43–0.58 58.4% 36.0% 80/193 (41.5%)
9 Le et al.(2008) 193 68/193 (35.2%) 0.57 0.50–0.64 39.2% 42.4% 108/193 (56.0%)
10 Tate et al.(2005) 194 69/194 (35.6%) 0.50 0.43–0.58 59.2% 35.1% 80/194 (41.2%)
Predicting R1 after IDS
No. Model No. of patients Residual tumor <1cm AUC 95% CI FN rate NPV Patients assigned to the good responder
1 Zeng et al.(2016) 193 160/193 (82.9%) 0.51 0.44–0.59 81.8% 82.5% 39/193 (20.2%)
2 Pelissier et al.(2016) 184 155/184 (84.2%) 0.54 0.44–0.64 44.8% 81.4% 114/193 (59.1%)
3 Morimoto et al.(2016) 193 160/193 (82.9%) 0.52 0.42–0.61 39.4% 81.7% 122/193 (63.2%)
4 Mahdi et al.(2015) 201 166/201 (82.6%) 0.55 0.47–0.64 65.7% 84.6% 52/201 (25.9%)
5 Pelissier et al.(2014) 184 155/184 (84.2%) 0.51 0.41–0.61 62.1% 83.9% 72/184 (39.1%)
6 Furukawa et al.(2013) 193 160/193 (82.9%) 0.54 0.46–0.62 56.3% 86.7% 133/193 (68.9%)
7 Rodriguez et al.(2012) 193 160/193 (82.9%) 0.54 0.46–0.62 75.8% 81.2% 60/193 (31.1%)
8 Vasudev et al.(2011) 194 162/194 (83.5%) 0.52 0.42–0.61 56.3% 84.2% 80/193 (41.5%)
9 Le et al.(2008) 193 160/193 (82.9%) 0.51 0.41–0.60 45.5% 82.4% 108/193 (56.0%)
10 Tate et al.(2005) 194 162/194 (83.5%) 0.50 0.41–0.60 59.4% 83.3% 80/194 (41.2%)
https://doi.org/10.1371/journal.pone.0203366.t003
CA-125 in advanced-stage ovarian cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0203366 September 6, 2018 6 / 11
cross-sectional radiological findings, is currently used to determine the resectability for IDS in
patients with advanced-stage ovarian cancer [19]. Reduction of CA-125 could be used in the
neoadjuvant setting to predict chemotherapy response. Patients who show no CA-125
response to NAC often do not undergo IDS and have a poor prognosis [20].
The previous 10 models [9–18] investigated various cut-off values of CA-125 to find good
and poor responders among patients who underwent NAC in advanced-stage ovarian cancer.
In the models for predicting optimal cytoreduction, it is important to increase the optimiza-
tion of IDS for good responders, as well as to reduce futile surgery for the poor responders.
Therefore, futile surgery can be reduced if the model has a high NPV (>90%), with an FN rate
of<5%. Continuing second-line chemotherapy alone can provide reasonable disease control
in patients who were unsuitable for optimal IDS in the poor responder subgroup [21]. All
models showed poor performance in terms of discrimination in predicting optimal cytoreduc-
tion after NAC.
Fig 1. Receiver-operating characteristics curves of 10 models to predict platinum-resistance.
https://doi.org/10.1371/journal.pone.0203366.g001
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It is important to reduce the incidence of platinum-resistance in the good responder patient
subgroup treated with NAC. In the models for predicting platinum-resistance, a low NPV
increases the possibility of administering futile chemotherapy. Patients with poor response to
platinum-based NAC show a short-term therapeutic effect from chemotherapy and a high
probability of platinum-resistant disease. Therefore, clinical trials using other targeted agents
with molecular profiling should be considered over conventional chemotherapy. Although
CA-125-based parameters showed some accuracy in predicting platinum-resistance in the 10
models, no single model showed a sufficient NPV (highest value = 82.0%).
The 10 models showed moderate accuracy for predicting PFS and OS. The iAUC for
predicting PFS ranged from 0.65–0.68, and OS ranged from 0.65–0.70. The iAUC is a
weighted average of the AUC over the entire follow-up period, as well as a measure of pre-
dictive accuracy of the model during follow-up. None of the 10 models displayed a suffi-
cient iAUC (highest value = 0.70). Harrell’s C-index estimates the ability of the serum CA-
125 kinetic parameters to discriminate patients with respect to their recurrence, mortality,
and survival. All 10 models showed a moderate Harrell’s C-index for predicting PFS and
OS; Harrell’s C-index for predicting PFS ranged from 0.65–0.69 and OS ranged from 0.70–
0.76. All models predicting OS showed a relatively high value of Harrell’s C-index com-
pared to models used for predicting PFS. These results suggest that survival outcomes are
better in the good responder subgroup. In the good responder patient subgroup, NAC may
improve overall patient quality-of-life and functional status [22], in addition to provide
favorable perioperative morbidity. NAC can result in adequate tumor shrinkage and effec-
tively increase the feasibility of optimal cytoreductive surgery [23]. Furthermore, survival
outcomes can be improved by performing the same regimen for POAC, in which efficacy
has been shown for NAC. In the poor responder subgroup, even when optimal cytoreduc-
tion is achieved and postoperative adjuvant chemotherapy is performed, there is still a high
risk of recurrence.
Our study had some limitations. First, the entire patient cohort was not used to assess each
model. This was due to not all the models being designed for the evaluation of the response to
NAC for the same patients. Most models were designed to evaluate patients with FIGO stage
IIIC and IV [9, 10, 12, 13, 15, 18]. Moreover, model 2 and 8 were designed to evaluate patients
with FIGO stage III and IV [11, 16], whereas model 9 was designed to predict the response to
NAC with FIGO stage II to IV [17], and model 6 was designed to predict the response to NAC
in only FIGO stage III [14]. Second, CA-125 was the only variable used, with the cut-off value
being set to predict patients that would be good responders in all models.
To the best of our knowledge, this is the first study comparing 10 previous studies using
various kinetic parameters of serum CA-125 as a predictive factor in patients of advanced-
stage ovarian cancer treated with NAC. None of the proposed kinetic parameters utilizing
serum CA-125 showed high accuracy in predicting optimal cytoreduction or platinum-resis-
tance in patients undergoing IDS after NAC. All models showed moderate accuracy for the
prediction of survival outcomes. Future prospective studies are required to explore reliable
strategies that will allow for the stratification of NAC treatment response groups for predicting
optimal cytoreduction at IDS to prevent futile surgery, platinum-resistance to tailor appropri-
ate POAC, and survival outcomes.
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